Status:
COMPLETED
Telemedicine for Patients With an Hybrid Closed Loop System
Lead Sponsor:
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Conditions:
Diabetes Mellitus, Type 1
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The primary objective is to assess the impact on quality of life after a follow-up program using a telemedicine platform designed for patients with DM1 treated with an hybrid closed loop insulin infus...
Eligibility Criteria
Inclusion
- Diagnostic criteria for DM1 according to ADA
- They must have access to the technology that allows monitoring (mobile phone and / or computer as well as having an internet connection)
- Acceptance of participation in the study and signing of the informed consent
Exclusion
- Gestation
- Institutionalization, serious or terminal illness or renal replacement therapy.
- Inability to undertake the training and / or acquire the degree of knowledge to use the telemedicine platform.
- Refusal to participate in the study or to sign the informed consent
Key Trial Info
Start Date :
May 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 27 2023
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT04900636
Start Date
May 1 2021
End Date
January 27 2023
Last Update
September 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lía Nattero Chávez
Madrid, Please Select, Spain, 28034